NCT00366288View on ClinicalTrials.gov

Study Evaluating PAZ-417 in Healthy Young/Elderly

CompletedOBSERVATIONAL
Enrollment

56

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

March 31, 2008

Study Completion Date

March 31, 2008

Conditions
Alzheimer Disease
Interventions
DRUG

PAZ-417

2.5 mg, 5, 10, 25, 50 mg - fasted in healthy young 10 mg - food effect in healthy young 5 and 25 mg -fasted healthy elderly.

Trial Locations (1)

85044

Phoenix

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00366288 - Study Evaluating PAZ-417 in Healthy Young/Elderly | Biotech Hunter | Biotech Hunter